Fingolimod for Type 2 Diabetes Mellitus

NCT05307731 PHASE4 RECRUITING

The aim of this study is to explore the efficacy and safety of Fingoland in the treatment of type 2 diabetes. A total of 40 patients were randomly divided into two groups. One group was treated with fingolimod, another group was given guideline based treatment. The changes of islet function in patients with glycosylated hemoglobin, insulin and C-peptide were observed .

Details

Lead sponsor	General Hospital of Shenyang Military Region
Phase	PHASE4
Status	RECRUITING
Enrolment	40
Start date	Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Mar 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Diabetes Mellitus, Type 2

Interventions

• Fingolimod
• guideline-based treatment for DM

Countries

China